Second Genome Secures $42.6 Million in Series B Financing Led by Pfizer Venture Investments and Roche Venture Fund

April 20, 2016, South San Francisco, CA

Read More

Second Genome Announces Inflammatory Bowel Disease Research Alliance with the APC Microbiome Institute at University College Cork

April 27, 2015, South San Francisco, CA

Read More

Second Genome Advances Lead Microbiome Drug Development Program in Phase I Clinical Trial as a Treatment for Inflammatory Bowel Disease

January 12, 2015, South San Francisco, CA

Read More

Second Genome and Mayo Clinic Enter Collaboration to Develop Microbiome Therapeutics in Multiple Diseases

October 7, 2014, South San Francisco, CA

Read More

Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Scientific Officer

September 2, 2014, South San Francisco, CA

Read More

Second Genome Enters Into Agreement with Pfizer Inc. on Microbiome Research Initiative in Obesity

May 2, 2014, South San Francisco, CA

Read More

Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis

June 5, 2013, San Bruno, CA

Read More

Second Genome Sponsors American Gut Initiative to Identify Links Between Type 2 Diabetes and the Human Microbiome

January 3, 2013, San Francisco, CA

Read More